Please use this identifier to cite or link to this item: https://doi.org/10.1097/MD.0000000000004566
Title: Growth differentiation factor-15 and white matter hyperintensities in cognitive impairment and dementia
Authors: Chai, Yuek Ling 
Hilal, Saima 
Chong, Jenny PC 
Ng, Yan Xia 
Liew, Oi Wah 
Xu, Xin 
Ikram, Mohammad Kamran 
Venketasubramanian, Narayanaswamy 
Richards, A Mark 
Lai, Mitchell KP 
Chen, Christopher P 
Keywords: Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
biomarker
cerebrovascular disease
cognitive impairment
dementia
growth differentiation factor-15
white matter hyperintensities
BETA SUPERFAMILY MEMBER
FACTOR-15/MACROPHAGE INHIBITORY CYTOKINE-1
ALZHEIMERS-DISEASE
CEREBROVASCULAR-DISEASE
VASCULAR DEMENTIA
ISCHEMIC-STROKE
ASSOCIATION
PATHOLOGY
INJURY
BRAIN
Issue Date: 1-Aug-2016
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Citation: Chai, Yuek Ling, Hilal, Saima, Chong, Jenny PC, Ng, Yan Xia, Liew, Oi Wah, Xu, Xin, Ikram, Mohammad Kamran, Venketasubramanian, Narayanaswamy, Richards, A Mark, Lai, Mitchell KP, Chen, Christopher P (2016-08-01). Growth differentiation factor-15 and white matter hyperintensities in cognitive impairment and dementia. MEDICINE 95 (33). ScholarBank@NUS Repository. https://doi.org/10.1097/MD.0000000000004566
Abstract: Vascular pathology plays an important role in the development of cognitive decline and dementia. In this context, growth differentiation factor-15 (GDF-15) has been suggested to be a biomarker due to its regulatory roles in inflammatory and trophic responses during tissue injury. However, limited data exist on the associations of GDF-15 with either cerebrovascular disease (CeVD) burden or the spectrum of cognitive impairment. Therefore, we aimed to study peripheral levels of GDF-15 incognitive impairment no dementia (CIND) or Alzheimer disease (AD) subjects assessed for CeVD using a case-control cohort design, with cases recruited from memory clinics and controls from memory clinics and the community. All subjects underwent detailed neuropsychological assessment, 3-Tesla magnetic resonance imaging, and venous blood draw. Subjects were classified as CIND or AD based on clinical criteria, while significant CeVD was defined as the presence of cortical infarcts and/or 2 lacunes or more, and/or confluent white matter hyperintensities (WMHs) in 2 or more brain regions. A total of 324 subjects were included in the study, of whom 80 had no cognitive impairment, 144 CIND and 100with AD. Higher GDF-15 levels were significantly associated with disease groups, especially in the presence of CeVD, namely, CIND with CeVD (odds ratios [OR]: 7.21; 95% confidence interval [CI]: 2.14-24.27) and AD with CeVD (OR: 21.87; 95% CI: 2.01-237.43). Among the different CeVD markers, only WMH was associated with higher GDF-15 levels (OR: 3.97; 95% CI: 1.79-8.83). The associations between GDF-15 and cognitive impairment as well as with WMH remained significant after excluding subjects with cardiovascular diseases. In conclusion, we showed that increased GDF-15 may be a biomarker for CIND and AD in subjects with WMH.
Source Title: MEDICINE
URI: https://scholarbank.nus.edu.sg/handle/10635/188487
ISSN: 00257974
15365964
DOI: 10.1097/MD.0000000000004566
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
50 Chai GDF15 Harmonization MED 2016.pdf208.45 kBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

23
checked on Nov 26, 2021

Page view(s)

67
checked on Nov 18, 2021

Download(s)

1
checked on Nov 18, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.